(AOF) – American stock markets are subject to profit taking, particularly technology stocks. The yield on the American 10-year bond fell below 4.60%, but it still gained 1.1 basis points to 4.593%. The United States recorded a larger trade deficit than expected in November Around 5:40 p.m., the Dow Jones lost 0.83% to 42968.22 points while the Nasdaq Composite fell 1.88% to 19644.93 points. Volumes are low due to the absence of many operators two sessions before the end of the stock market year.
If American “megacaps” are weighing on the trend today, they have had another very favorable year in 2024. Apple, Nvidia, Alphabet (Google), Amazon, Meta, Microsoft and Tesla soared again. The Apple firm is thus approaching 4,000 billion dollars in capitalization, unheard of. The most exclusive club on the “finance” planet could welcome an 8th member: Broadcom. The semiconductor and software specialist currently weighs $1,122 billion on the stock market.
Today’s economic figures
The United States recorded a trade deficit of $102.9 billion in November, higher than the consensus of $101.3 billion and the October consensus of $98.3 billion.
Values to follow today
BioNTech
BioNTech is expected to fall in pre-market trading on Wall Street after announcing a compromise with the University of Pennsylvania (Penn) in a dispute which has opposed them since last summer. The establishment has been suing the group since August, accusing the company of having underpaid royalties for patents covering the technology used in its anti-Covid 19 vaccines. BioNtech could pay up to 467 million dollars to Penn, including $400 million in royalties for calendar years 2020-2023.
Outlook Therapeutics
Outlook Therapeutics is expected to rise in pre-market trading on Wall Street after the publication of its annual results. The American biotech company reported a net loss of $75.4 million, or $4.06 per basic and diluted share, compared to $59.0 million, for the previous fiscal year. As of September 30, 2024, Outlook Therapeutics had $14.9 million in cash and cash equivalents. The biotech is developing Lytenava, approved for the treatment of AMD (age-related macular degeneration).
UnitedHealth
The American health insurance group UnitedHealth and Amedisys have agreed to extend the deadline for their merger, according to a document filed with the SEC. Originally scheduled for December 2024, the deal was delayed due to legal difficulties, including an action by the U.S. Department of Justice (DOJ). UnitedHealth had offered $3.6 billion to acquire Amedisys.
